| Literature DB >> 28011817 |
Mihoko Sutoh Yoneyama1, Yuki Tobisawa2, Shingo Hatakeyama2, Misaki Sato1, Kiyoshi Tone3, Yota Tatara4, Ikuko Kakizaki4, Tomihisa Funyu1, Minoru Fukuda5, Senji Hoshi6, Chikara Ohyama2, Shigeru Tsuboi1,2.
Abstract
Anti-tumour immunity by cytotoxic T-lymphocytes (CTLs) is essential to suppress tumour progression. Cancer cells that evade CTL immunity proliferate in the host, promoting metastasis, but mechanisms underlying this capacity remain unknown. Here we report that bladder cancer cells metastasized to lymph nodes evade CTL immunity by a new mechanism via altered glycosylation. CTLs normally recognize and kill cancer cells presenting antigenic peptides on human leukocyte antigen (HLA) class I. We show bladder cancer cells expressing the O-glycan processing enzyme, core2 β-1,6-N-acetylglucosaminyltransferase (C2GnT) exhibit HLA class I O-glycan modified with poly-N-acetyllactosamine and are highly susceptible to CTL. In those cells, poly-N-acetyllactosamine on HLA class I O-glycan binds galectin-3 to form a cell-surface molecular lattice, enabling efficient cell-surface retention of HLA class I. In contrast, bladder cancer cells in which C2GnT is downregulated show decreased levels of poly-N-acetyllactosamine on HLA class I O-glycans, attenuating lattice formation and reducing the cell-surface half-life of HLA class I. These tumour cells present antigenic peptides less efficiently, thereby evading CTL lysis and facilitating metastasis.Entities:
Keywords: O-glycan; cancer immunology; cytotoxic T-lymphocyte (CTL); galectin; immune evasion
Mesh:
Substances:
Year: 2017 PMID: 28011817 DOI: 10.1093/jb/mvw096
Source DB: PubMed Journal: J Biochem ISSN: 0021-924X Impact factor: 3.387